Last reviewed · How we verify
NCT04871633
Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore
NA trial testing Remdesivir in COVID-19 in 66 participants. Completed in 30 December 2020.
15 November 2020
Quick facts
| Lead sponsor | King Edward Medical University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 66 |
| Start date | 1 August 2020 |
| Primary completion | 15 November 2020 |
| Estimated completion | 30 December 2020 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Remdesivir (remdesivir) — full drug profile →
- Conventional
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
King Edward Medical University
Who can join
12 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Currently, several drugs including Remdesivir, hydroxychloroquine, chloroquine, ritonavir+lopinavir, Tocilizumab, Arbidol and interferon are under randomised controlled trials (RCTs) for efficacy and/or safety evaluations in patients with COVID-19 in different countries. Remdesivir (GS-5734) is among these investigational drugs and some studies reported promising results. Remdesivir is a nucleotide analogue intravenous pro-drug developed by Gilead Sciences, an American biopharmaceutical company, for treatment of Ebola virus during the 2014 Ebola outbreak in Western Africa. Remdesivir shows broad-spectrum antiviral activity against many RNA viruses including SARS-CoV-2 through blocking RNA polymerase thereby terminating RNA transcription. Remdesivir was among the first treatments used in China as the outbreak emerges and it has been reported as potential treatment options for COVID-19 in the USA, China and Italy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prospective Medicinal Plants and Their Phytochemicals Shielding Autoimmune and Cancer Patients Against the SARS-CoV-2 Pandemic: A Special Focus on Matcha.
Kiriacos CJ, Khedr MR, Tadros M, Youness RA. · · 2022 · cited 5× · PMID 35664773 · DOI 10.3389/fonc.2022.837408
Verify or expand the search:
- PubMed search for NCT04871633
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Remdesivir
Trials testing the same drug.
- NCT06817889 — Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals · Phase 2 · recruiting
- NCT05911906 — An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID. · Phase 4 · completed
- NCT06860282 — A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects · Phase 1 · completed
- NCT05502081 — Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hos · Phase 4 · completed
- NCT05780541 — PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) · Phase 3 · terminated
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other King Edward Medical University trials
Trials by the same sponsor.
- NCT07480447 — Comparison of Pain Reduction in Painful Chronic Wounds With and Without Fat Grafting · NA · not yet recruiting
- NCT07428265 — Comparison of Wound Healing for Diabetic Carbuncle Treated With Incision and Drainage Technique Using Cruciate Incision · NA · recruiting
- NCT07368439 — Effect of Feedback-Based Balance Training on Balance and Gait in Cancer Patients With Chemotherapy-Induced Peripheral Ne · NA · not yet recruiting
- NCT07210424 — Comparative Study on the Post-operative Pain and Other Outcomes of Mesh Fixation With Prolene vs Vicryl vs Skin Staples · not yet recruiting
- NCT07267260 — Evaluating the Efficacy of Vonoprazan in Preventing Post-Endoscopic Variceal Band Ligation Ulcers: A Randomized Controll · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04871633 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by King Edward Medical University
- Last refreshed: 4 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04871633.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing